Cat. No.
MABL-3877
Application
Blocking, in vivo, inhibition, SPR, WB, IHC
Isotype
Engineer antibody
Species Reactivity
Human
Clone No.
AbAb01‑alpha2Ct
From
Recombinant Antibody
Specificity
The original antibody is specific for the C‑terminal telopeptide of the α2(I) chain of human collagen I.
Alternative Names
Collagen alpha‑2(VIII) chain; Endothelial collagen
UniProt
P25067
Immunogen
The original antibody was raised against a synthetic peptide (GGGYDFGYDGDFYRA) whose sequence corresponds to that of the C‑terminal telopeptide of the alpha2 chain (α2Ct).
Application Notes
The original format of the antibody specifically recognized C‑terminal telopeptide of the α2(I) chain of human collagen I, as determined by Western blot assays. The presence of the original format of the antibody decreased the rate of cleavage of procollagen chains in a concentration‑dependent fashion. The original format of the antibody blocked telopeptide‑mediated collagen/collagen interactions reducing the amount of collagen fibrils accumulated in vitro and in keloid‑like organotypic constructs (Chung et al., 2008; PMID: 18650436). The human IgG1 and F(ab')2 formats of the antibody recognized C‑terminal telopeptide of the α2(I) chain of human collagen by western blot analysis. The binding affinity of the mIgA, hIgG1 and hF(ab')2 fragments to procollagen I was measured by surface plasmon resonance ( Kd=0.2 nM , 3.2 nM and 2.8 nM respectively). The hIgG1 format of the antibody inhibited fibril formation in vitro. The hIgG1 format of the antibody inhibited the formation of collagen deposits in cell layers. The mIgA format of the antibody immunostained human skin sample, while the hIgG1 version immunostained mouse skin and thymus (Fertala et al., 2013; PMID: 23586407). The scFv format of the antibody bound exclusively to the pro‑α2 chain by western blot analysis. The binding affinity of the scFv fragment to procollagen I was measured by surface plasmon resonance (KD=75 nM). The scFv format of the antibody completely inhibited the formation of collagen fibril at scFv:collagen molar ratio of 16:1 or resulted in the formation of a mixed population of collagen assemblies at ratio 4:1. The scFv fragment primarily interacted with collagen fibrils at the boundaries of a gap region in which the scFv's epitope, i.e. the α2Ct. The scFv variant of the antibody blocked the deposition of collagen fibrils in the gap region existing between cells isolated from tendon and tendon sheath without altering the ability of cells to proliferate and migrate into the border region (Fertala et al., 2014; PMID: 24195607). The original antibody was employed in a in vivo clinically relevant arthrofibrosis model to study its broad mechanisms (Steplewski et al., 2021; PMID: 34492074).
Antibody First Published
Chung et al. Collagen fibril formation. A new target to limit fibrosis J Biol Chem. 2008 Sep 19;283(38):25879-86. doi: 10.1074/jbc.M804272200. Epub 2008 Jul 23. PMID:18650436
Note on publication
The original paper describes the generation and characterization of the antibody.
Size
100 μg Purified antibody.
Concentration
1 mg/ml.
Purification
Protein A affinity purified
Buffer
PBS with 0.02% Proclin 300.
Storage Recommendation
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C.


